Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The May 2013 issue of Biopharma Dealmakers showcases companies with partnering opportunities and contains a special feature on oncology. This week, find out about how you can collaborate with Merck.
SciBX Collections Macrocycles and constrained peptides
This special collection explores the factors behind the growing interest in macrocycles and constrained peptides over the last five years and their effect on drug discovery.
MPS IIIA: gene therapy for brain and body Michael J. Haas doi:10.1038/scibx.2013.709 Within a year of reporting preclinical proof of concept for a systemically delivered MPS IIIA gene therapy, Autonomous University of Barcelona researchers have substantially improved efficacy in the CNS while still treating peripheral organs via intracerebral delivery. Partner Esteve is now raising funds to enter the clinic. Full Text | PDF
MJFF's progress in markers Michael J. Haas doi:10.1038/scibx.2013.710 To identify clinical populations for testing new therapies for Parkinson's disease, the Michael J. Fox Foundation made available the first set of data and samples from its LRRK2 Cohort Consortium and presented preliminary data from its Parkinson's Progression Marker Initiative. Full Text | PDF
Silencing neuropathic pain C. Simone Fishburn doi:10.1038/scibx.2013.711 Researchers at The Johns Hopkins University School of Medicine have identified a long noncoding RNA that is upregulated by nerve injury associated with neuropathic pain. The molecule silences voltage-gated potassium channel Kv1.2 exclusively in damaged neurons and could thus be a new target for the indication. Full Text | PDF
Universal appeal for CARs Tracey Baas doi:10.1038/scibx.2013.712 MD Anderson and Sangamo are overcoming the need for autologous cells in CAR-expressing T cell–based immunotherapies. The group has used gene-modifying tools to mask donor-derived T cells from immune surveillance machinery in the recipient and is planning clinical trials with such cells targeting CD19. Full Text | PDF
Calcium channel N-type; calcium channel P/Q-type doi:10.1038/scibx.2013.713 Cell-based and mouse studies identified an agonist of N- and P/Q-type calcium channels that could help treat Lambert-Eaton myasthenic syndrome. Full Text | PDF
Ataxia telangiectasia mutated (ATM); DNA-dependent protein kinase (DNA-PK) doi:10.1038/scibx.2013.714 Mouse and cell culture studies suggest inhibiting the DNA-PK catalytic subunit could help treat ATM-deficient cancers. Full Text | PDF
Proteasome doi:10.1038/scibx.2013.715 Cell culture studies suggest a noncompetitive, imidazoline-based proteasome inhibitor could help treat cancer. Full Text | PDF
Stem cell factor receptor tyrosine kinase (c-Kit; KIT; CD117) doi:10.1038/scibx.2013.716 In vitro studies suggest quinazoline-pyrazolourea–based KIT inhibitors could help treat Gleevec imatinib–resistant gastrointestinal stromal tumors (GISTs). Full Text | PDF
E2F1; tumor protein p73 (TP73; p73) doi:10.1038/scibx.2013.717 Cell culture and mouse studies suggest combining methotrexate with an antifolate prodrug could help treat melanoma. Full Text | PDF
Mitochondrial oxidative phosphorylation doi:10.1038/scibx.2013.718 Cell culture and mouse studies suggest inhibiting oxidative phosphorylation could help treat drug-resistant melanoma. Full Text | PDF
Peroxiredoxin 2 (PRDX2) doi:10.1038/scibx.2013.719 Mouse studies suggest compounds that mimic PRDX2 activity could help prevent melanoma metastasis. Full Text | PDF
Aurora kinase A (AURKA; aurora-A); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC) doi:10.1038/scibx.2013.720 Cell culture and mouse studies suggest AURKA inhibitors that disrupt the AURKA-NMYC complex could help treat neuroblastomas. Full Text | PDF
Septin 4 (SEPT4; ARTS) doi:10.1038/scibx.2013.721 In vitro and mouse studies suggest inhibiting SEPT4 could help treat wounds and promote hair follicle regeneration. Full Text | PDF
HBV core protein doi:10.1038/scibx.2013.722 In vitro and mouse studies suggest the arginine-rich domain of HBV core protein could help treat bacterial infections. Full Text | PDF
Not applicable doi:10.1038/scibx.2013.723 In vitro and mouse studies suggest silver could be used to potentiate the effects of antibiotics to treat bacterial infections. Full Text | PDF
Unknown doi:10.1038/scibx.2013.724 Cell culture studies suggest anthracimycin derivatives could help treat bacterial infections. Full Text | PDF
Unknown doi:10.1038/scibx.2013.725 Cell culture and mouse studies suggest selective estrogen receptor modulators (SERMs) could help treat Ebola virus infection. Full Text | PDF
Not applicable doi:10.1038/scibx.2013.726 Rodent studies suggest the addition of Baraclude entecavir to plasmid- and adenoviral vector–based vaccination protocols could help treat chronic HBV infection. Full Text | PDF
Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2′-oxidase (dprE1); M. tuberculosis molybdopterin biosynthesis protein (moeW) doi:10.1038/scibx.2013.727 Mouse and cell culture studies suggest an inhibitor of dprE1 and moeW could help treat drug-resistant tuberculosis infection. Full Text | PDF
Estrogen receptor doi:10.1038/scibx.2013.728 Cell culture and mouse studies suggest estradiol could help treat UTIs in postmenopausal women. Full Text | PDF
Unknown doi:10.1038/scibx.2013.729 Cell culture and mouse studies suggest guaifenesin could help treat diabetic neuropathy. Full Text | PDF
Neurotrophic tyrosine kinase receptor 2 (NTRK2; TrkB) doi:10.1038/scibx.2013.730 Mouse studies suggest NTRK2 inhibitors could help treat temporal lobe epilepsy. Full Text | PDF
Purinergic receptor P2Y G protein–coupled 1 (P2RY1; P2Y1) doi:10.1038/scibx.2013.731 Cell culture studies identified dual-acting antioxidant and P2Y1 receptor agonist nucleotides that could be useful as neuroprotectants. Full Text | PDF
CREB binding protein (CREBBP; CBP); E1A binding protein p300 (EP300; p300) doi:10.1038/scibx.2013.732 Mouse and cell culture studies suggest CBP and p300 agonists could be useful for improving cognitive function. Full Text | PDF
μ-Opioid receptor (OPRM1; MOR); cannabinoid CB1 receptor (CNR1) doi:10.1038/scibx.2013.733 SAR and mouse studies identified a bivalent dual MOR agonist and CNR1 antagonist that could be useful for treating pain. Full Text | PDF
Potassium channel Kv1.2 (KCNA2) doi:10.1038/scibx.2013.734 Rat studies suggest targeting KCNA2 antisense long noncoding RNA (lncRNA) could help treat neuropathic pain. Full Text | PDF
Solute carrier family 22 organic cation transporter member 2 (SLC22A2; OCT2) doi:10.1038/scibx.2013.735 Mouse and cell culture studies suggest inhibiting OCT2 could help decrease oxaliplatin-induced neurotoxicity. Full Text | PDF
Matrix metalloproteinase 9 (MMP9)-deficient mice for modeling pre-eclampsia doi:10.1038/scibx.2013.736 Mouse fetuses and pregnant mice lacking Mmp9 could be useful in identifying therapies to treat pre-eclampsia. Full Text | PDF
Organoid model for colon cancer derived from primary intestinal epithelial cells doi:10.1038/scibx.2013.737 Primary intestinal epithelial cells modified to form tumorigenic organoids in 3D cell culture could provide an in vitro model for colon cancer. Full Text | PDF
Retinal delivery of gene therapy via intravitreal injection of an engineered adeno-associated viral (AAV) vector doi:10.1038/scibx.2013.738 Intravitreal injection of an engineered AAV vector could enable retinal gene therapy. Full Text | PDF
Serum protease–degradable peptide linkers to control antimicrobial peptide release doi:10.1038/scibx.2013.739 Customized peptide linkers that are degraded by serum proteases could be used to control the release of therapeutic peptides from pegylated prodrugs. Full Text | PDF
CpG-depleted adeno-associated virus (AAV) vectors for improved delivery to skeletal muscle doi:10.1038/scibx.2013.740 AAV vectors depleted of the toll-like receptor 9 (TLR9) ligand CpG could improve the success of gene therapy for musculoskeletal diseases. Full Text | PDF
Crystal structure of variable lymphocyte receptor (VLR) VLRB.aGPA.23 with a tumor-associated glycan antigen doi:10.1038/scibx.2013.741 The crystal structure of VLR bound to a tumor-associated glycan antigen could be useful for designing tumor-targeting VLRs for therapeutic and diagnostic applications. Full Text | PDF
Near-infrared fluorescent proteins (iRFPs) that allow multicolor, in vivo imaging doi:10.1038/scibx.2013.742 In vitro and mouse studies identified four iRFPs that could be used for noninvasive, multicolor imaging in animals. Full Text | PDF
Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer
Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment